Objectives: In the absence of large, prospective, placebo-controlled studies of longer
duration, substantial evidence regarding the safety and risk of testosterone (T) therapy (TTh) …

Background Testosterone exerts some effects on the cardiovascular system that could be
considered beneficial; some other effects may potentially increase the risk of cardiovascular …

Background The relationship between testosterone (T) and cardiovascular (CV) risk in men
is conflicting. Aim To verify whether T therapy (TTh) represents a possible risk factor for CV …

Background/objectives Long-term testosterone therapy (TTh) in men with hypogonadism
has been shown to improve all components of the metabolic syndrome. In this study, we …

Background Testosterone is the standard treatment for male hypogonadism, but there is
uncertainty about its cardiovascular safety due to inconsistent findings. We aimed to provide …

Background The cardiovascular safety of testosterone-replacement therapy in middle-aged
and older men with hypogonadism has not been determined. Methods In a multicenter …

Aims The aim of this study was to assess cardiovascular (CV) safety of testosterone
replacement therapy (TRT) in a large, diverse cohort of European men with hypogonadism …

The role of testosterone (T) in the cardiovascular (CV) health of men is controversial. Some
data suggest that hypogonadism is associated with CV mortality but not morbidity, however …

Background Although male hypogonadism is associated with increased cardiovascular
events (CVE), recent concerns are that testosterone supplementation may increase CVE …

Context: The widespread use of T therapy, particularly in aging males, necessitates
knowledge of the relationship between T and the cardiovascular system. Evidence …